The improved efficacy of a fixed‐dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis

Murdoch, Robert; Bareille, Philippe; Ignar, Diane M.; Miller, Sam; Gupta, Ashutosh; Boardley, Rebecca L.; Zieglmayer, Petra; Zieglmayer, René; Lemel, P.; Horak, Friedrich

doi:10.1111/cea.12556

Cited by 18 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recommendations have been refined with RWE and chamber studies (Table IV). [20][21][22][23][24]38,39,41,42,45,50 The algorithm proposed in Fig 3 is also supported by the present data.…”

Section: Next-generation Aria-grade Guidelinessupporting

confidence: 83%

“…37 In the Ontario and Vienna allergen exposure chambers, several medications have been tested (Table III). 26,27,[38][39][40][41][42][43][44][45][46][47][48][49][50][51] The Ontario chamber studies show the rapid onset of efficacy for azelastine and its combinations. There does not seem to be a difference between azelastine alone or in combination.…”

Section: Speed Of Onset Of Action Of Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

Bousquet

Schünemann

Togias

et al. 2020

Journal of Allergy and Clinical Immunology

336

246

View full text Add to dashboard Cite

Selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on (1) patient empowerment, preferences, and age; (2) prominent symptoms, symptom severity, and multimorbidity; (3) efficacy and safety of treatment 1 ; (4) speed of onset of action of treatment; (5) current treatment; (6) historic response to treatment; (7) effect on sleep and work productivity 2,3 ; (8) self-management strategies; and (9) resource use. 4,5 An algorithm was devised 5 and digitalized 6 to step up or step down allergic rhinitis treatment based on control. However, its

show abstract

“…Recommendations have been refined with RWE and chamber studies (Table IV). [20][21][22][23][24]38,39,41,42,45,50 The algorithm proposed in Fig 3 is also supported by the present data.…”

Section: Next-generation Aria-grade Guidelinessupporting

confidence: 83%

Section: Speed Of Onset Of Action Of Medicationsmentioning

confidence: 99%

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

Bousquet

Schünemann

Togias

et al. 2020

Journal of Allergy and Clinical Immunology

336

246

View full text Add to dashboard Cite

show abstract

“…Furthermore, data from AEC studies are considered to be more robust than park studies [51]. Several nasal drugs were tested in the pollen exposure chambers of Ontario [17,[52][53][54] and Vienna [55][56][57]. Ontario's chamber studies show the rapid onset of action of azelastine and its combinations, including MPAzeFlu.…”

Section: Infobox 2 Recommendations For Pharmacotherapy For Allergic Rmentioning

confidence: 99%

“…Other intranasal H1 antihistamines showed a slower onset of action. However, intranasal corticosteroids (INCSs) (alone or with oral H1 antihistamines) did not show an onset of action for 2 h. The Vienna Chamber studies show that azelastine and levocabastinin combined with fluticasone furoate are the fastest acting drugs in comparison to oral H1-antihistamines or ICNSs alone [55][56][57].…”

Section: Infobox 2 Recommendations For Pharmacotherapy For Allergic Rmentioning

confidence: 99%

ARIA guideline 2019: treatment of allergic rhinitis in the German health system

et al. 2019

View full text Add to dashboard Cite

Background The number of patients affected by allergies is increasing worldwide. The resulting allergic diseases are leading to significant costs for health care and social systems. Integrated care pathways are needed to enable comprehensive care within the national health systems. The ARIA (Allergic Rhinitis and its Impact on Asthma) initiative develops internationally applicable guidelines for allergic respiratory diseases. Methods ARIA serves to improve the care of patients with allergies and chronic respiratory diseases. In collaboration with other international initiatives, national associations and patient organizations in the field of allergies and respiratory diseases, real-life integrated care pathways have been developed for a digitally assisted, integrative, individualized treatment of allergic rhinitis (AR) with comorbid asthma. In the present work, these integrated care pathways have been adapted to the German situation and health system. Results The present ICP (integrated care pathways) guideline covers key areas of the care of AR patients with and without asthma. It includes the views of patients and other healthcare providers. Discussion A comprehensive ICP guideline can reflect real-life care better than traditional guideline models.

show abstract

“…Clinical and Experimental Allergy also published randomized controlled trial data in 2015 demonstrating short‐term efficacy for a combined nasal corticosteroid and antihistamine preparation and longer term efficacy for a short course of peptide‐based cat immunotherapy .…”

Section: Asthma and Rhinitismentioning

confidence: 99%

Developments in the field of clinical allergy in 2015 through the eyes of Clinical and Experimental Allergy

Roberts

Boyle

Bryce

et al. 2016

Clin Experimental Allergy

View full text Add to dashboard Cite

SummaryIn the second of two papers, we describe developments in the field of clinical allergy as documented by Clinical and Experimental Allergy in 2015. Epidemiology, clinical allergy, asthma and rhinitis are all covered.In this second of two reviews, we discuss the new findings in the field of allergy in 2015 focusing on clinical aspects. These highlight the contribution published in Clinical and Experimental Allergy. We focus on epidemiology, clinical allergy, asthma and rhinitis. Epidemiology GeneralThe research field of allergy-related diseases is complex since we often lack firm data on exposure, and outcome is not easy to estimate as diagnosis is often more subjective compared to other disease areas. Additionally we lack high-quality registries. Such registries are based on a doctor's willingness to enter patient data. Such registers give us a good description of entered patients although we do not know what data are excluded. However, the situation is improving with i-technology. In some EU countries, there are now inpatient, outpatient and national registers including registers for twins. However, a lot of information for epidemiological research in the field of allergy related diseases is still based on questionnaire data, where the quality of the collected information is not always known.

show abstract

The improved efficacy of a fixed‐dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis

Abstract: These results suggest that once daily FF/LEVO FDC could provide a clinical therapeutic advantage to existing standard monotherapies in the treatment of moderate-to-severe AR, and support progression to evaluation in larger phase III clinical studies.

Cited by 18 publications

References 37 publications

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

ARIA guideline 2019: treatment of allergic rhinitis in the German health system

Developments in the field of clinical allergy in 2015 through the eyes of Clinical and Experimental Allergy

Contact Info

Product

Resources

About